AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30826617 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary nitrate (SN)
Number of subjects: 0
Study 30826617 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary sulfate PM2.5 (SS)
Number of subjects: 0
Study 28643265 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg every 6 months)
Number of subjects: 1479
Study 26114379 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release (DR) prednisone
Number of subjects: 110
Study 23241006 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 88
Study 23241006 — intervention group
Group type: COMPARATOR
Intervention: Light-emitting diode (LED) placebo
Number of subjects: 88
Study 23241006 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 21980964 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg
Number of subjects: 0
Study 21980964 — intervention group
Group type: COMPARATOR
Intervention: Combination of lisinopril 10 mg and diclofenac sodium 100 mg
Number of subjects: 0
Study 18096409 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sucrose
Number of subjects: 12
Study 18096409 — intervention group
Group type: COMPARATOR
Intervention: sucralose
Number of subjects: 12
Study 17063170 — intervention group
Group type: EXPERIMENTAL
Intervention: P400 (400 mg phosphate)
Number of subjects: 8
Study 17063170 — intervention group
Group type: EXPERIMENTAL
Intervention: P800 (800 mg phosphate)
Number of subjects: 8
Study 17063170 — intervention group
Group type: EXPERIMENTAL
Intervention: P1200 (1200 mg phosphate)
Number of subjects: 8
Study 12622767 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod (6 mg b.d.)
Number of subjects: 20
Study 12622767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12622767 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod
Number of subjects: 20
Study 10967376 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleft palate patients with CAD
Number of subjects: 58
Study 10967376 — intervention group
Group type: COMPARATOR
Intervention: Cleft palate patients without CAD (control)
Number of subjects: 58
Study 9082928 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation (TLI)
Number of subjects: 19
Study 9082928 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 19
Study 8368545 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg of morphine
Number of subjects: 90
Study 8368545 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg of epinephrine
Number of subjects: 90
Study 8368545 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.2 mg of morphine and 0.2 mg of epinephrine
Number of subjects: 90
Study 8368545 — intervention group
Group type: COMPARATOR
Intervention: Spinal bupivacaine alone
Number of subjects: 90
Study 3545737 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 128
Study 3545737 — intervention group
Group type: COMPARATOR
Intervention: Amiloride HCl 5 mg + Hydrochlorothiazide 50 mg (AHCZ)
Number of subjects: 128
Study 3545737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 29309832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (300,000 IU oral doses at 8 weeks interval)
Number of subjects: 31
Study 29309832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation
Number of subjects: 31
Study 26749356 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar chart (print advertisement)
Number of subjects: 2504
Study 26749356 — intervention group
Group type: EXPERIMENTAL
Intervention: Table (print advertisement)
Number of subjects: 2504
Study 26749356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictograph (print advertisement)
Number of subjects: 2504
Study 26749356 — intervention group
Group type: EXPERIMENTAL
Intervention: Any visual aid (television advertisement)
Number of subjects: 2504
Study 26749356 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar chart (television advertisement)
Number of subjects: 2504
Study 26749356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictograph (television advertisement)
Number of subjects: 2504
Study 26749356 — intervention group
Group type: EXPERIMENTAL
Intervention: Table (television advertisement)
Number of subjects: 2504
Study 26749356 — intervention group
Group type: COMPARATOR
Intervention: No visual aid (print and television advertisements)
Number of subjects: 2504
Study 25903215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day)
Number of subjects: 33
Study 25903215 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (5 mg/day)
Number of subjects: 33
Study 23658114 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir intensification
Number of subjects: 13
Study 21041275 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0
Study 21041275 — intervention group
Group type: COMPARATOR
Intervention: Tramadol hydrochloride
Number of subjects: 0
Study 18708936 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 28
Study 18708936 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 28
Study 16861614 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle case management (CM)
Number of subjects: 147
Study 16861614 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 147
Study 14522295 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol combination (Cosopt)
Number of subjects: 38
Study 14522295 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 38
Study 10795763 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium butyrate (4 g/day) plus oral mesalazine (2.4 g/day)
Number of subjects: 30
Study 10795763 — intervention group
Group type: COMPARATOR
Intervention: Oral mesalazine plus placebo
Number of subjects: 30
Study 8633143 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐EOB‐DTPA (12.5, 25, and 50 mumol per kilogram of body weight)
Number of subjects: 33
Study 8633143 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐EOB‐DTPA (12.5 mumol)
Number of subjects: 33
Study 8633143 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath‐hold, T1‐weighted, fast low‐angle shot pulse sequence
Number of subjects: 33
Study 8633143 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐EOB‐DTPA
Number of subjects: 33
Study 1571381 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 g of cefodizime
Number of subjects: 326
Study 1571381 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g of cefodizime
Number of subjects: 326
Study 1571381 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g of cefodizime
Number of subjects: 326
Study 1571381 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime (all doses)
Number of subjects: 326
Study 6488703 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of calcium (increased plasma calcium concentration by about 0.5 mmol/l)
Number of subjects: 8
Study 6488703 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of calcium infusion after 46 min
Number of subjects: 8
Study 6488703 — intervention group
Group type: COMPARATOR
Intervention: Infusion of sodium nitroprusside
Number of subjects: 8
Study 6488703 — intervention group
Group type: COMPARATOR
Intervention: Infusion of noradrenaline
Number of subjects: 8
Study 30284097 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure mask (CPAP), oxygen at 6 L/min, 5-15 cm H2O
Number of subjects: 40
Study 30284097 — intervention group
Group type: COMPARATOR
Intervention: Simple oxygen mask, oxygen at 6 L/min
Number of subjects: 40
Study 30216648 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg
Number of subjects: 1489
Study 30216648 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1489
Study 27252150 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline health-related quality of life (HRQoL) assessed using EORTC QLQ-C30 and BN20 brain cancer module
Number of subjects: 134
Study 27252150 — intervention group
Group type: EXPERIMENTAL
Intervention: Final prognostic model based on HRQoL and clinical parameters
Number of subjects: 134
Study 25204510 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel ultrasound device
Number of subjects: 20
Study 25204510 — intervention group
Group type: COMPARATOR
Intervention: Conventional device
Number of subjects: 20
Study 22080364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough test
Number of subjects: 92
Study 22080364 — intervention group
Group type: COMPARATOR
Intervention: No cough test
Number of subjects: 92
Study 20181990 — intervention group
Group type: EXPERIMENTAL
Intervention: Golfers
Number of subjects: 23
Study 20181990 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 23
Study 17678469 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV/ddI-containing regimen
Number of subjects: 0
Study 16084879 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of tibolone
Number of subjects: 352
Study 16084879 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of E2 plus 1 mg of norethisterone acetate (E2/NETA)
Number of subjects: 352
Study 16084879 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate (CEE/MPA)
Number of subjects: 352
Study 16084879 — intervention group
Group type: COMPARATOR
Intervention: No menopausal therapy (control)
Number of subjects: 352
Study 12115339 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving training intervention (two in-person and four telephone sessions over 12 weeks)
Number of subjects: 164
Study 12115339 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving training intervention
Number of subjects: 164
Study 12115339 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 164
Study 10408487 — intervention group
Group type: EXPERIMENTAL
Intervention: M. vaccae
Number of subjects: 347
Study 10408487 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 347
Study 10408487 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 347
Study 7473832 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (25% of total calories)
Number of subjects: 411
Study 7473832 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran (25 g daily)
Number of subjects: 411
Study 7473832 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention of low fat and wheat bran
Number of subjects: 411
Study 7473832 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 411
Study 2258344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin (800 mg per day)
Number of subjects: 189
Study 2258344 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin (4 g per day) plus Gentamicin (240 mg per day im)
Number of subjects: 189
Study 6112329 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12
Study 6112329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31669049 — intervention group
Group type: EXPERIMENTAL
Intervention: 975 mg oral acetaminophen
Number of subjects: 100
Study 30550890 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving education on maternal health
Number of subjects: 1206
Study 30550890 — intervention group
Group type: EXPERIMENTAL
Intervention: Best friend's use of maternal care
Number of subjects: 1206
Study 30550890 — intervention group
Group type: EXPERIMENTAL
Intervention: Head of the household
Number of subjects: 1206
Study 30550890 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience of postpartum complications
Number of subjects: 1206
Study 27437928 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino Acid-based Formula (AAF)
Number of subjects: 65
Study 27437928 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively Hydrolyzed Whey Formula (eHWF)
Number of subjects: 65
Study 27437928 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 65
Study 27437928 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino Acid-based Formula (AAF) and Extensively Hydrolyzed Whey Formula (eHWF)
Number of subjects: 65
Study 26383910 — intervention group
Group type: EXPERIMENTAL
Intervention: BITSEA (intervention condition)
Number of subjects: 2610
Study 26383910 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control condition)
Number of subjects: 2610
Study 23430981 — intervention group
Group type: EXPERIMENTAL
Intervention: MTRR haplotypes
Number of subjects: 1966
Study 23430981 — intervention group
Group type: COMPARATOR
Intervention: Other haplotypes
Number of subjects: 1966
Study 20661637 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief integrative multiple behavior intervention
Number of subjects: 479
Study 20661637 — intervention group
Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 479
Study 20029102 — intervention group
Group type: COMPARATOR
Intervention: Forward (arch) foot position
Number of subjects: 10
Study 17968020 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone plus capecitabine (Ixabepilone 40 mg/m² IV on day 1 of a 21-day cycle plus capecitabine 2000 mg/m² orally on days 1-14 of a 21-day cycle)
Number of subjects: 752
Study 17968020 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone (2500 mg/m² on the same schedule)
Number of subjects: 752
Study 17968020 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone plus capecitabine
Number of subjects: 752
Study 17968020 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 752
Study 16045668 — intervention group
Group type: COMPARATOR
Intervention: Axillary approach for brachial plexus block
Number of subjects: 30
Study 16045668 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraclavicular approach for brachial plexus block
Number of subjects: 30
Study 12121393 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% tea tree oil solution
Number of subjects: 158
Study 12121393 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% tea tree oil solution
Number of subjects: 158
Study 12121393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 12121393 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea tree oil (both concentrations)
Number of subjects: 158
Study 9893074 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary unsupervised aerobic and step training (twice per week)
Number of subjects: 49
Study 9893074 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 49
Study 7758402 — intervention group
Group type: EXPERIMENTAL
Intervention: Marihuana cigarettes containing 1.26% delta 9-THC
Number of subjects: 18
Study 7758402 — intervention group
Group type: EXPERIMENTAL
Intervention: Marihuana cigarettes containing 2.53% delta 9-THC
Number of subjects: 18
Study 7758402 — intervention group
Group type: COMPARATOR
Intervention: Placebo cigarettes
Number of subjects: 18
Study 7758402 — intervention group
Group type: EXPERIMENTAL
Intervention: All marihuana groups (1.26% and 2.53% delta 9-THC)
Number of subjects: 18
Study 2185822 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone 0 mg (placebo)
Number of subjects: 230
Study 2185822 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 25 mg
Number of subjects: 230
Study 2185822 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg
Number of subjects: 230
Study 2185822 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 100 mg
Number of subjects: 230
Study 2185822 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (all doses)
Number of subjects: 230
Study 391754 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol, 15 mg/day
Number of subjects: 22
Study 391754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30848805 — intervention group
Group type: EXPERIMENTAL
Intervention: Low BMI/Low Alcohol
Number of subjects: 91552
Study 30848805 — intervention group
Group type: EXPERIMENTAL
Intervention: Low BMI/High Alcohol
Number of subjects: 91552
Study 30848805 — intervention group
Group type: EXPERIMENTAL
Intervention: High BMI/Low Alcohol
Number of subjects: 91552
Study 30848805 — intervention group
Group type: COMPARATOR
Intervention: High BMI/High Alcohol (reference group)
Number of subjects: 91552
Study 27977309 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated inhalation maneuver
Number of subjects: 32
Study 27977309 — intervention group
Group type: COMPARATOR
Intervention: Uncoordinated inhalation maneuver
Number of subjects: 32
Study 26124485 — intervention group
Group type: EXPERIMENTAL
Intervention: New ointment containing several antioxidants
Number of subjects: 152
Study 26124485 — intervention group
Group type: COMPARATOR
Intervention: Urea cream
Number of subjects: 152
Study 26124485 — intervention group
Group type: EXPERIMENTAL
Intervention: New ointment
Number of subjects: 152
Study 23728549 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg bid for 14 days
Number of subjects: 64
Study 23728549 — intervention group
Group type: EXPERIMENTAL
Intervention: GERD (+) patients
Number of subjects: 64
Study 23728549 — intervention group
Group type: COMPARATOR
Intervention: GERD (-) patients
Number of subjects: 64
Study 21570071 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance-guided focused ultrasound surgery (FUS) treatment of uterine fibroids
Number of subjects: 1
Study 19447262 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboccipital muscle inhibition technique
Number of subjects: 70
Study 19447262 — intervention group
Group type: COMPARATOR
Intervention: Placebo technique
Number of subjects: 70
Study 16249194 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 55
Study 16249194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 16249194 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (in vitro)
Number of subjects: 55
Study 14761114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A-treated patients
Number of subjects: 23
Study 14761114 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontitis-affected patients
Number of subjects: 23
Study 14761114 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study 11034245 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 5-fluorouracil (5-FU) 450 mg/m2/day with leucovorin 20 mg/m2/day for 12 cycles (n=74)
Number of subjects: 166
Study 11034245 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doxifluridine 900 mg/m2/day with leucovorin 20 mg/m2/day for 12 cycles (n=92)
Number of subjects: 166
Study 11034245 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life scores
Number of subjects: 166
Study 8769611 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/kg intravenous hyperimmune globulin (IVIG)
Number of subjects: 0
Study 8769611 — intervention group
Group type: COMPARATOR
Intervention: Albumin placebo
Number of subjects: 0
Study 1427133 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 18
Study 1427133 — intervention group
Group type: COMPARATOR
Intervention: Acetazolamide
Number of subjects: 18
Study 1427133 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Timolol and Acetazolamide
Number of subjects: 18
Study 6427816 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg diazepam
Number of subjects: 120
Study 6427816 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg diazepam
Number of subjects: 120
Study 6427816 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg diazepam
Number of subjects: 120
Study 6427816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30796816 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Number of subjects: 72
Study 30796816 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Number of subjects: 72
Study 30796816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 30796816 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 72
Study 28619236 — intervention group
Group type: EXPERIMENTAL
Intervention: ISP+FO
Number of subjects: 73
Study 28619236 — intervention group
Group type: COMPARATOR
Intervention: Control (wheat flour+corn oil)
Number of subjects: 73
Study 27035272 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced B vitamins
Number of subjects: 330
Study 27035272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 24788589 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal yoga
Number of subjects: 59
Study 24788589 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 59
Study 22054112 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentils
Number of subjects: 24
Study 22054112 — intervention group
Group type: EXPERIMENTAL
Intervention: Navy beans
Number of subjects: 24
Study 22054112 — intervention group
Group type: EXPERIMENTAL
Intervention: Chickpeas
Number of subjects: 24
Study 22054112 — intervention group
Group type: EXPERIMENTAL
Intervention: All pulses
Number of subjects: 24
Study 22054112 — intervention group
Group type: COMPARATOR
Intervention: Control (pasta and sauce)
Number of subjects: 24
Study 19117641 — intervention group
Group type: EXPERIMENTAL
Intervention: AD cases with neuronal immunoreactivity for epigenetic markers and factors
Number of subjects: 0
Study 19117641 — intervention group
Group type: COMPARATOR
Intervention: AD neurons
Number of subjects: 0
Study 18324902 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl citrate (group A, n = 30)
Number of subjects: 58
Study 18324902 — intervention group
Group type: COMPARATOR
Intervention: Parecoxib sodium (group B, n = 28)
Number of subjects: 58
Study 15756185 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 45
Study 15756185 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5%
Number of subjects: 45
Study 15756185 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 45
Study 12186348 — intervention group
Group type: EXPERIMENTAL
Intervention: Emdogain + Bio-Oss (BDX)
Number of subjects: 24
Study 12186348 — intervention group
Group type: COMPARATOR
Intervention: Bio-Oss (BDX) alone
Number of subjects: 24
Study 10489654 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychomotor Activation Programme (PAP)
Number of subjects: 134